Please assess the completion status of the following clinical trial:

Trial Title: Stem Cell Study for Patients With Heart Disease

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~-Chronic severe CAD patients fulfilling all the following criteria are considered suitable for inclusion in the study.~1. At least 6 months since last episode of myocardial infarction or at least 3 months since initial anginal episode.~2. Patients fulfilling either of the following criteria based on the extent of CAD by coronary angiography and LVEF by echocardiography.~   * Patients with single vessel CAD and LVEF \< 50%~  * Patients with multivessel CAD~3. Reversible myocardial ischemia as revealed by sestamibi SPECT stress myocardial scintigraphy.~4. Patients for whom angioplasty and bypass are not indicated because of anatomical or procedural reasons or frequent reocclusion/restenosis following traditional revascularization.~5. Age is between 20 and 80 (at time of consent).~6. Exercise tolerance time (ETT) duration ≥ 3 minutes and \< 13 minutes on a modified Bruce protocol on 2 consecutive tests (\> 24 hours but \< 2 weeks apart), with the difference between the 2 exercise times within 25% of their mean (Patients should not be informed of exercise restrictions required for entry into the study).~7. Patients who can give informed consent themselves in writing.~Exclusion Criteria:~* Any one of the following exclusion criteria is sufficient to disqualify a patient from the study.~  1. Sustained ventricular tachycardia in a 24-hour ECG.~ 2. Chronic atrial fibrillation.~ 3. Less than 6 months since last episode of cerebral infarction.~ 4. Less than 6 months since last coronary angioplasty or less than 3 months since last bypass surgery.~ 5. Patients with unstable angina, with a treatment rating of 3 in the Braunwald system (refer to 5.4.), but a severity of III and a clinical rating of B or C.~ 6. Presence of left ventricular thrombus by echocardiography~ 7. Patients with a malignant tumor\*.~ 8. Patients with diabetic proliferating retinopathy\*\* (new Fukuda classification BI to BV).~ 9. Patients with chronic rheumatoid arthritis.~ 10. Patients with a history of severe allergic reactions or side effects to G-CSF preparations or apheresis.~ 11. Patients with hematological disease (leukemia, myeloproliferative disease, or myelodysplastic syndromes).~ 12. Patients currently suffering from or having a history of interstitial pneumonitis.~ 13. Patients for whom cranial MRA reveals cerebral aneurysm.~ 14. Patients for whom abdominal CT or ultrasonography reveals splenomegaly.~ 15. Patients with cirrhosis of the liver.~ 16. Patients who cannot discontinue Warfarin.~ 17. Leukocytes less than 4,000/µL or exceeding 10,000/µL.~ 18. Platelets less than 100,000/µL.~ 19. Hemoglobin less than 10 g/dL.~ 20. AST (GOT) exceeding 100 IU/L or ALT (GPT) exceeding 100 IU/L.~ 21. Patients for whom it is impossible to perform both cardiac MRI and left ventriculography (LVG) (see 9.2.4 for cardiac MRI details and 9.2.9 for LVG details).~ 22. Patients with gate disturbance for reasons other than CAD (such as critical limb ischemia, sciatic neuralgia, or vasculitis), making exercise tolerance evaluation on a treadmill with stress ECG difficult.~ 23. Pregnant or nursing patients, those who may be pregnant, or those who plan on becoming pregnant before the end of the study period.~ 24. Any other reason that the Clinical Supervisors or Clinical Researchers may have for considering a case unsuitable for the study.

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).